NCT07646171 EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)
| NCT ID | NCT07646171 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tel-Aviv Sourasky Medical Center |
| Condition | Hormone Receptor Positive Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 19 participants |
| Start Date | 2022-09-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 19 participants in total. It began in 2022-09-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This phase II, open-label, single-arm, study investigates the clinical benefit of everolimus combined with endocrine therapy (ET) in hormone receptor-positive (HR+), metastatic breast cancer (MBC) patients who progressed on prior PI3K inhibitor therapy (+ ET). The trial aims to determine if sequential inhibition of the PI3K/AKT/mTORC1 pathway retains efficacy post-PI3K inhibitor resistance, hypothesizing that everolimus will demonstrate a response rate exceeding the historical 9.5% observed in the BOLERO2 trial.
Eligibility Criteria
Inclusion Criteria: * HR+MBC with PI3Kmut Post CDK 4/6+ET Post PI3K inhibitor+ET Exclusion Criteria: * Women who didn't receive anti-PI3K
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07646171 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Hormone Receptor Positive Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07646171 currently recruiting?
Yes, NCT07646171 is actively recruiting participants. Contact the research team at hananm@tlvmc.gov.il for enrollment information.
Where is the NCT07646171 trial being conducted?
This trial is being conducted at Tel Aviv, Israel.
Who is sponsoring the NCT07646171 clinical trial?
NCT07646171 is sponsored by Tel-Aviv Sourasky Medical Center. The trial plans to enroll 19 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.